IP International Journal of Comprehensive and Advanced Pharmacology
Official Publication of Khyati Education And Research Foundation
Official Publication of Khyati Education And Research Foundation
Print ISSN:-2581-5555
Online ISSN:-2456-9542
CODEN : IIJCDU
Original Article
Author Details :
Volume : 5, Issue : 3, Year : 2020
Article Page : 130-137
https://doi.org/10.18231/j.ijcaap.2020.027
Abstract
Ebola virus disease (EVD) may be a painful reminder as an epidemic anywhere which might be a risk
everywhere. The World Health Security Agenda pursue to enforce public health systems in most affected
countries to eliminate the spreads before they become emergencies. Virus infection occurs in but half
patients and it takes place most typically within the GI tract. The symptoms headway the period of time
and patients tolerate from dehydration, multi organ failure, hypotension, stupor, confusion resulting in
unstable shock and eventually death. Pre-clinical evaluation is additionally underway for various vaccine
candidates. It’s been hypothesized that infection of macrophages is one in all the causes for the development
of haemorrhage. The target of the proposed work is to review out the rationale and management of
filovirus and communicating clear and accurate information to all or any stakeholders of filovirus and
communicating clear and accurate information to all or any stakeholders including the overall public which
is that the need of the hour.
Keywords: Ebola virus disease, Viral haemorrhagic fever, Filovirus, Outbreak, Pathogenesis, Treatment, Management.
How to cite : Himani, Anand A , Barwal A , Qadrie Z L, Gautam S P, Novel frontiers on ebola virus disease management: An update. IP Int J Compr Adv Pharmacol 2020;5(3):130-137
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
